Cancer diagnostics startup Pairidex raised $4.89 million in oversubscribed seed financing to advance FusionMRD, an RNA-based droplet digital PCR test for monitoring minimal residual disease in gene fusion-driven blood cancers. The company said the lab-developed assay is already commercially available through its CLIA-certified and CAP-accredited laboratory. FusionMRD is designed for patient-specific monitoring, with initial focus on acute myeloid leukemia cases driven by gene fusions. Pairidex plans to use the funding to support commercialization efforts, laboratory operations, and additional clinical studies to broaden evidence for treatment decision-making. The financing underscores continued investor interest in liquid-biopsy-style monitoring tools that aim to move MRD testing from research into routine clinical pathways for molecularly defined subsets.